These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25085702)

  • 21. Loss of MicroRNA-155 protects the heart from pathological cardiac hypertrophy.
    Seok HY; Chen J; Kataoka M; Huang ZP; Ding J; Yan J; Hu X; Wang DZ
    Circ Res; 2014 May; 114(10):1585-95. PubMed ID: 24657879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the highly abundant circular RNA circSlc8a1 in cardiomyocytes attenuates pressure overload induced hypertrophy.
    Lim TB; Aliwarga E; Luu TDA; Li YP; Ng SL; Annadoray L; Sian S; Ackers-Johnson MA; Foo RS
    Cardiovasc Res; 2019 Dec; 115(14):1998-2007. PubMed ID: 31114845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microarray analysis of Akt1 activation in transgenic mouse hearts reveals transcript expression profiles associated with compensatory hypertrophy and failure.
    Schiekofer S; Shiojima I; Sato K; Galasso G; Oshima Y; Walsh K
    Physiol Genomics; 2006 Oct; 27(2):156-70. PubMed ID: 16882883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489.
    Wang K; Liu F; Zhou LY; Long B; Yuan SM; Wang Y; Liu CY; Sun T; Zhang XJ; Li PF
    Circ Res; 2014 Apr; 114(9):1377-88. PubMed ID: 24557880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA-1 downregulation increases connexin 43 displacement and induces ventricular tachyarrhythmias in rodent hypertrophic hearts.
    Curcio A; Torella D; Iaconetti C; Pasceri E; Sabatino J; Sorrentino S; Giampà S; Micieli M; Polimeni A; Henning BJ; Leone A; Catalucci D; Ellison GM; Condorelli G; Indolfi C
    PLoS One; 2013; 8(7):e70158. PubMed ID: 23922949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pivotal Role of Regulator of G-protein Signaling 12 in Pathological Cardiac Hypertrophy.
    Huang J; Chen L; Yao Y; Tang C; Ding J; Fu C; Li H; Ma G
    Hypertension; 2016 Jun; 67(6):1228-36. PubMed ID: 27091895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct and indirect involvement of microRNA-499 in clinical and experimental cardiomyopathy.
    Matkovich SJ; Hu Y; Eschenbacher WH; Dorn LE; Dorn GW
    Circ Res; 2012 Aug; 111(5):521-31. PubMed ID: 22752967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA-133 controls cardiac hypertrophy.
    Carè A; Catalucci D; Felicetti F; Bonci D; Addario A; Gallo P; Bang ML; Segnalini P; Gu Y; Dalton ND; Elia L; Latronico MV; Høydal M; Autore C; Russo MA; Dorn GW; Ellingsen O; Ruiz-Lozano P; Peterson KL; Croce CM; Peschle C; Condorelli G
    Nat Med; 2007 May; 13(5):613-8. PubMed ID: 17468766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-29a-3p attenuates ET-1-induced hypertrophic responses in H9c2 cardiomyocytes.
    Li M; Wang N; Zhang J; He HP; Gong HQ; Zhang R; Song TF; Zhang LN; Guo ZX; Cao DS; Zhang TC
    Gene; 2016 Jul; 585(1):44-50. PubMed ID: 26992639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-106a promotes cardiac hypertrophy by targeting mitofusin 2.
    Guan X; Wang L; Liu Z; Guo X; Jiang Y; Lu Y; Peng Y; Liu T; Yang B; Shan H; Zhang Y; Xu C
    J Mol Cell Cardiol; 2016 Oct; 99():207-217. PubMed ID: 27565029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy.
    Dong DL; Chen C; Huo R; Wang N; Li Z; Tu YJ; Hu JT; Chu X; Huang W; Yang BF
    Hypertension; 2010 Apr; 55(4):946-52. PubMed ID: 20177001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors.
    Ganesan J; Ramanujam D; Sassi Y; Ahles A; Jentzsch C; Werfel S; Leierseder S; Loyer X; Giacca M; Zentilin L; Thum T; Laggerbauer B; Engelhardt S
    Circulation; 2013 May; 127(21):2097-106. PubMed ID: 23625957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MALAT1-mediated recruitment of the histone methyltransferase EZH2 to the microRNA-22 promoter leads to cardiomyocyte apoptosis in diabetic cardiomyopathy.
    Wang C; Liu G; Yang H; Guo S; Wang H; Dong Z; Li X; Bai Y; Cheng Y
    Sci Total Environ; 2021 Apr; 766():142191. PubMed ID: 33097254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The alteration of protein prenylation induces cardiomyocyte hypertrophy through Rheb-mTORC1 signalling and leads to chronic heart failure.
    Xu N; Guan S; Chen Z; Yu Y; Xie J; Pan FY; Zhao NW; Liu L; Yang ZZ; Gao X; Xu B; Li CJ
    J Pathol; 2015 Apr; 235(5):672-85. PubMed ID: 25385233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of MicroRNA-146a and Overexpression of Its Target Dihydrolipoyl Succinyltransferase Protect Against Pressure Overload-Induced Cardiac Hypertrophy and Dysfunction.
    Heggermont WA; Papageorgiou AP; Quaegebeur A; Deckx S; Carai P; Verhesen W; Eelen G; Schoors S; van Leeuwen R; Alekseev S; Elzenaar I; Vinckier S; Pokreisz P; Walravens AS; Gijsbers R; Van Den Haute C; Nickel A; Schroen B; van Bilsen M; Janssens S; Maack C; Pinto Y; Carmeliet P; Heymans S
    Circulation; 2017 Aug; 136(8):747-761. PubMed ID: 28611091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy.
    Bernardo BC; Nguyen SS; Winbanks CE; Gao XM; Boey EJ; Tham YK; Kiriazis H; Ooi JY; Porrello ER; Igoor S; Thomas CJ; Gregorevic P; Lin RC; Du XJ; McMullen JR
    FASEB J; 2014 Dec; 28(12):5097-110. PubMed ID: 25145628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiac Disease Status Dictates Functional mRNA Targeting Profiles of Individual MicroRNAs.
    Matkovich SJ; Dorn GW; Grossenheider TC; Hecker PA
    Circ Cardiovasc Genet; 2015 Dec; 8(6):774-84. PubMed ID: 26553694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel role for caspase-activated DNase in the regulation of pathological cardiac hypertrophy.
    Gao L; Huang K; Jiang DS; Liu X; Huang D; Li H; Zhang XD; Huang K
    Hypertension; 2015 Apr; 65(4):871-81. PubMed ID: 25646292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNA-101 inhibits rat cardiac hypertrophy by targeting Rab1a.
    Wei L; Yuan M; Zhou R; Bai Q; Zhang W; Zhang M; Huang Y; Shi L
    J Cardiovasc Pharmacol; 2015 Apr; 65(4):357-63. PubMed ID: 25850725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Delivery of miR-148a Suppresses Ventricular Dilation in Heart Failure.
    Raso A; Dirkx E; Philippen LE; Fernandez-Celis A; De Majo F; Sampaio-Pinto V; Sansonetti M; Juni R; El Azzouzi H; Calore M; Bitsch N; Olieslagers S; Oerlemans MIFJ; Huibers MM; de Weger RA; Reckman YJ; Pinto YM; Zentilin L; Zacchigna S; Giacca M; da Costa Martins PA; López-Andrés N; De Windt LJ
    Mol Ther; 2019 Mar; 27(3):584-599. PubMed ID: 30559069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.